Fareston
(toremifene)ApprovedSmall molecule
Kyowa Kirin Co., Ltd.Toremifene is used to treat breast cancer in postmenopausal women. It works by blocking estrogen in the body, which helps slow or stop the growth of estrogen-dependent breast cancer cells.[2] Fareston is currently approved and in use across 5 indications[4].[1]
Fareston is one of 51 small molecule programs targeting Bone Fracture. It is currently in Approved.
5
Indications
23
Total Trials
1
Active Trials
50
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
744 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Fareston
Kyowa Kirin Co., Ltd.Approved
Adenocard
AstellasPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Duragesic
CCephalon
Preclinical
Rilvegostomig
AstraZenecaPreclinical
Ablavar
LLantheus Medical Imaging
Preclinical
4SCAR T Cells
SShenzhen Geno-Immune Medical Institute
Preclinical
Liposomal Irinotecan and Apatinib
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Preclinical
QS21
MMemorial Sloan Kettering Cancer Center
Preclinical
Tetracycline Hydrochloride
EEuropean Organisation for Research and Treatment of Cancer - EORTC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer12 trials
Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer
Unknown status·NN.N. Petrov National Medical Research Center of Oncology·Phase 2·NCT02506790·96 enrolled
Show 9 more trials
Prostate Cancer2 trials
Intraepithelial Neoplasia1 trial
6 more indications
Ultrasound1 trial
Changes in Breast 3D Ultrasound Measurements Using Toremifene
Completed·—·Phase 3·NCT01417754·20 enrolled
Clinical Trial1 trial
Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets
Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT02353429·25 enrolled
COVID-191 trial
Selective Estrogen Modulation and Melatonin in Early COVID-19
Withdrawn·—·Phase 2·NCT04531748
Endocrine Therapy1 trial
Desmoid Tumor1 trial
Toremifene in Treating Patients With Desmoid Tumors
Completed·—·Phase 2·NCT00002595·72 enrolled
Magnetic Resonance Imaging (MRI)1 trial
The Effect of Toremifene Treatment to the Magnetic Resonance Imaging (MRI) Findings in Premenstrual Mastalgia
Completed·—·Phase 3·NCT00534846·10 enrolled
Regulatory
FDA Approval Timeline[5]
May 29, 1997
FARESTON
NDA NDA020497
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Fareston drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for toremifene. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Estrogen Receptor Modulator[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company